Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RAG-01 |
| Synonyms | |
| Therapy Description |
RAG-01 is a small activating RNA targeting CDKN1A (p21), which upregulates CDKN1A (p21) gene expression, potentially resulting in antitumor activity (J Clin Oncol 2025 43: 16_suppl, e16587). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RAG-01 | RAG 01|RAG01 | RAG-01 is a small activating RNA targeting CDKN1A (p21), which upregulates CDKN1A (p21) gene expression, potentially resulting in antitumor activity (J Clin Oncol 2025 43: 16_suppl, e16587). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06351904 | Phase I | RAG-01 | A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guerin (BCG) Therapy | Recruiting | AUS | 0 |